137 related articles for article (PubMed ID: 11562446)
1. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.
Burgess AJ; Pavey S; Warrener R; Hunter LJ; Piva TJ; Musgrove EA; Saunders N; Parsons PG; Gabrielli BG
Mol Pharmacol; 2001 Oct; 60(4):828-37. PubMed ID: 11562446
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Rosato RR; Almenara JA; Grant S
Cancer Res; 2003 Jul; 63(13):3637-45. PubMed ID: 12839953
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
4. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells.
Donadelli M; Costanzo C; Faggioli L; Scupoli MT; Moore PS; Bassi C; Scarpa A; Palmieri M
Mol Carcinog; 2003 Oct; 38(2):59-69. PubMed ID: 14502645
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells.
Liu PY; Chan JY; Lin HC; Wang SL; Liu ST; Ho CL; Chang LC; Huang SM
Mol Cancer Res; 2008 Jul; 6(7):1204-14. PubMed ID: 18644983
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Rosato RR; Almenara JA; Yu C; Grant S
Mol Pharmacol; 2004 Mar; 65(3):571-81. PubMed ID: 14978235
[TBL] [Abstract][Full Text] [Related]
8. [Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines].
Chen YX; Fang JY; Lu J; Qiu DK
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):312-7. PubMed ID: 15059516
[TBL] [Abstract][Full Text] [Related]
9. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
Han JW; Ahn SH; Park SH; Wang SY; Bae GU; Seo DW; Kwon HK; Hong S; Lee HY; Lee YW; Lee HW
Cancer Res; 2000 Nov; 60(21):6068-74. PubMed ID: 11085529
[TBL] [Abstract][Full Text] [Related]
10. Trichostatin A inhibits proliferation and induces expression of p21WAF and p27 in human brain tumor cell lines.
Wang ZM; Hu J; Zhou D; Xu ZY; Panasci LC; Chen ZP
Ai Zheng; 2002 Oct; 21(10):1100-5. PubMed ID: 12508652
[TBL] [Abstract][Full Text] [Related]
11. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.
Ryu JK; Lee WJ; Lee KH; Hwang JH; Kim YT; Yoon YB; Kim CY
Cancer Lett; 2006 Jun; 237(1):143-54. PubMed ID: 16009488
[TBL] [Abstract][Full Text] [Related]
12. Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.
Noh EJ; Jang ER; Jeong G; Lee YM; Min CK; Lee JS
Cancer Res; 2005 Dec; 65(24):11400-10. PubMed ID: 16357148
[TBL] [Abstract][Full Text] [Related]
13. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
14. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
Huang H; Reed CP; Zhang JS; Shridhar V; Wang L; Smith DI
Cancer Res; 1999 Jun; 59(12):2981-8. PubMed ID: 10383164
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.
De Schepper S; Bruwiere H; Verhulst T; Steller U; Andries L; Wouters W; Janicot M; Arts J; Van Heusden J
J Pharmacol Exp Ther; 2003 Feb; 304(2):881-8. PubMed ID: 12538846
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
[TBL] [Abstract][Full Text] [Related]
19. Anti-arthritic effects of combined treatment with histone deacetylase inhibitor and low-intensity ultrasound in the presence of microbubbles in human rheumatoid synovial cells.
Nakamura C; Matsushita I; Kosaka E; Kondo T; Kimura T
Rheumatology (Oxford); 2008 Apr; 47(4):418-24. PubMed ID: 18281366
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]